CAS NO.:919797-19-6 25I-NBOMe;2C-I-NBOMe C18H22INO3 Recreational Club Clinical Composite Psychoactive Aphrodisiac Designer Drug

Detail:

        25I-NBOMe (2C-I-NBOMe, Cimbi-5, also shortened to "25I") is a psychedelic hallucinogen that is used in biochemistry research for mapping the brains usage of the type 2A serotonin receptor and later also has been used for recreational purpose. It is derivative of the substituted phenethylamine 2C-I and is the most well-known member of the 25-NB family. It was discovered in 2003 by chemist Ralf Heim at the Free University of Berlin, who published his findings in his PhD dissertation. The compound was subsequently investigated by a team at Purdue University led by David Nichols.

        The carbon-11 labelled version of 25I-NBOMe, [11C]Cimbi-5, was synthesized and validated as a radiotracer for positron emission tomography (PET) in Copenhagen. Being the first 5-HT2A receptor full agonist PET radioligand, [11C]-CIMBI-5 shows promise as a more functional marker of these receptors, particularly in their high affinity states.

Street names and media nicknames for this drug are: "N-Bomb", "Solaris", "Smiles" or "Wizard".

Recreational use:

        Although 25I-NBOMe was discovered in 2003, it did not emerge as a common recreational drug until 2010, when it was first sold by vendors specialising in the supply of research chemicals. In a slang context, the name of the compound is often shortened to "25I" or is called "N-Bomb". According to a 2014 survey, 25I-NBOMe was the most frequently used of the NBOMe series. Case reports of 25I-NBOMe intoxication, with and without analytic confirmation of the drug in the body, were in 2013 becoming increasingly common in the medical literature.

        25I-NBOMe is widely rumored to be orally inactive; however, oral efficacy has not been disproven and apparent overdoses have occurred via oral administration. Common routes of administration include sublingual, buccal, and nasal/intranasal. For sublingual and buccal administration, 25I-NBOMe is often applied to sheets of blotter paper of which small portions (tabs) are held in the mouth to allow absorption through the oral mucosa. There are reports of intravenous injection of 25I-NBOMe solution and smoking the drug in powdered form.

        Due to its potency and much lower cost than so-called classical or traditional psychedelics, 25I-NBOMe blotters are sometimes misrepresented as, or mistaken for LSD blotters. It is dangerous to attempt to differentiate the two using sensory techniques (i.e. taste) but reagent testing (in particular Ehrlich's reagent) can easily differentiate ergolines from 25I-NBOMe via colour change. Small quantities of 25I-NBOMe can provide a large numbers of doses. Vendors may import 25I-NBOMe in bulk and resell individual doses for considerable profit.

Dosage:

        25I-NBOMe is potent, being active in sub-milligram doses. A common dose of the hydrochloride salt is 600–1,200 µg. The UK Advisory Council on the Misuse of Drugs states that a common dose is between 50 and 100 µg, although other sources indicate that these figures are incorrect; Erowid tentatively suggests that the threshold dosage for humans is 50–250 µg, with a light dose between 200–600 µg, a common dose at 500–800 µg, and a strong dose at 700–1500 µg. At this level of potency, it is not possible to accurately measure a single dose of 25I-NBOMe powder without an analytical balance, and attempting to do so may put the user at significant risk of overdose.

Effects:

        25I-NBOMe effects usually last 6–10 hours if taken sublingually or buccally. When it is insufflated, effects usually last 4–6 hours. However, effects can last significantly longer depending on dosage; durations longer than 12 hours have been reported.

        25I-NBOMe can also be vaporized and inhaled, this may cause significantly quicker effects and shorter duration as is expected from that route of administration. However, this route of administration is very dangerous, unless using precise liquid measurement, due to the difficulties of measuring and handling substances active in the microgram range.

        25I-NBOMe has similar effects to LSD, though users report more negative effects while under the influence and more risk of harm following use as compared to other classic psychedelics.

        Case reports of seven British males who presented to an emergency room following analytically confirmed 25I-NBOMe intoxication suggest the following potential adverse effects: "tachycardia (n = 7), hypertension (4), agitation (6), aggression, visual and auditory hallucinations (6), seizures (3), hyperpyrexia (3), clonus (2), elevated white cell count (2), elevated creatine kinase (7), metabolic acidosis (3), and acute kidney injury (1)."

Chemistry:

        Like other 2C-X-NBOMe molecules, 25I-NBOMe is a derivative of the 2C family of phenethylamines described by Alexander Shulgin in his book PiHKAL. Specifically, 25I-NBOMe is an N-benzyl derivative of the phenethylamine molecule 2C-I, formed by adding a 2-methoxybenzyl (BnOMe) onto the nitrogen (N) of the phenethylamine backbone. This substitution significantly increases the potency of the molecule.

        We can provide Hallucinogens;Serotonin receptor modulators;Ergolines;Amphetamine;Anorectics;Decongestants;Monoamine releasing agents;Phenethylamines;Anxiolytics;Benzodiazepines;GABAA receptor positive modulators;Recreational drug;Club drugs;Euphoriants;Opioid receptor modulators；Analgesics；Stimulants;Monoamine neurotoxins;Serotonin receptor modulators;Sigma receptor modulators;Anticonvulsants;Antidotes;Glycine receptor modulators;Toxins;Globular proteins;chemical warfare and other chemical reagent .

       You can send message to us if you not see what you want product in our Web ,we will provide synthetic services for you.The synthesis time usually need 1-5 days.Wishing you a happy shopping.

Warm prompt:Please use it for chemical experiment,We are not liable for any legal liability.